Media ReleasesImmutep

View All Immutep News

Immutep Announces Grant of European Patent for Eftilagimod Alpha in Combination with a PD-1 or PD-L1 Inhibitor

SYDNEY, AUSTRALIA – November 28, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 3242678) entitled "Combined Preparations for the Treatment of Cancer or Infection" by the European Patent Office.

The new patent protects Immutep’s intellectual property relating to combined preparations comprising its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 or PD-L1 inhibitor, and also the use of the combined preparations for the treatment of cancer or infection. Under the patent, efti and the PD-1 or PD-L1 inhibitor may be present in one combined dosage form, or as part of separate dosage forms for sequential administration of the respective active ingredients. The patent expiry date is 8 January 2036.

For further information please download PDF attached:
Download this document